Logo

Lundbeck’s Vyepti (eptinezumab) Receives EC’s Approval for the Treatment of Migraine

Share this

Lundbeck’s Vyepti (eptinezumab) Receives EC’s Approval for the Treatment of Migraine

Shots:

  • The marketing authorization is based on the P-III (PROMISE-1 & 2) trial evaluating the efficacy and safety of Vyepti vs PBO in ~2000 patients with migraine
  • The results showed a reduction in monthly migraine days over PBO & sustained for 12wk. dosing interval and duration of treatment 12 & 6mos. in PROMISE-1 & 2 trial, reduction in the prevalence of migraine (50%) for both doses of Vyepti on day 1 post-infusion & the effects on PROs were observed for ~96 wks.
  • The marketing authorization is valid in all EU Member States, Iceland, Norway, and Liechtenstein. The therapy was approved in the US for migraine & is expected to be launched in the EU in the coming mos.

Ref: Cision | Image: Medwatch

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions